Articles tagged with Oncology
Susan Band Horwitz, an NFCR fellow, has been named a Giant of Cancer Care for her pioneering work on Taxol and its role in stabilizing microtubules to prevent cancer cell growth. Her research enabled the development of life-saving medications for ovarian, breast, and lung cancers.
Christine Menias, MD, is recognized for her dedication to radiology education, with a notable track record of instructional courses and awards. She has been named the 2019 ARRS Distinguished Educator for her inspirational teaching and commitment to improving competence and patient outcomes.
The global HER2 testing survey reveals major access and affordability issues in low and middle income countries, with some upper middle income countries also affected. The study suggests that governments need better information to set planning priorities for investing in infrastructure, testing, and treatment.
A recent study published in JAMA found that magic mouthwash significantly reduced pain from oral mucositis, a common side effect of radiation therapy for head and neck cancers. The treatment, which contains diphenhydramine, lidocaine, and antacids, was well-tolerated by patients and outperformed placebo.
Consuming garlic and onions has been shown to lower the risk of colorectal cancer in a Chinese study involving 833 patients. Adults who ate high amounts of allium vegetables had an 79% lower chance of developing the disease compared to those who consumed low amounts.
A large European study found that small lung spots in rhabdomyosarcoma patients do not affect survival prospects or require aggressive treatment, unlike larger metastases.
The MYSTIC trial found that first line immunotherapy combination with durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer. However, a subgroup of patients with high tumour mutational burden showed improved overall survival with the combination treatment.
The NRG Oncology clinical trial BR001 found that SBRT is safe for patients with 2 metastases or 3-4 metastases in specific locations, including peripheral lung and abdomen/pelvic. The study showed zero protocol-defined dose-limiting toxicities across evaluable anatomic locations.
Oncologists require more education on the use of biosimilars, which could increase patient access to innovative therapies due to economic constraints. ESMO supports their use as cheaper alternatives to reference biologics, promoting sustainable and widely accessible cancer care.
Researchers found a link between higher levels of interleukin-10 (IL-10) and lower disease-free survival rates after radiotherapy. Elevated CRP levels, a marker of inflammation, were not associated with DFS.
A study found huge variations in time between European countries to reach health technology assessment decisions on new cancer drugs, with some taking over a year. The average decision time was longer than one year in England and Scotland compared to Germany and France.
Researchers examined federal payment databases to determine payments made to oncologists who authored studies in high-impact journals. The study found that a substantial proportion of payments were not disclosed, which could lead to bias and influence clinical trial results.
Investigative report finds 40 physician advisors took over $10,000 from drug makers after reviewing drugs, while 26 received more than $100,000 in post-hoc earnings. The FDA's honor system for disclosing financial interests may be ineffective in detecting conflicts of interest.
Fabrice Barresi has been awarded the Heine H. Hansen Award by European Society for Medical Oncology (ESMO) and International Association for the Study of Lung Cancer (IASLC). This award is presented annually at the European Lung Cancer Congress to a lung cancer investigator who has made a special contribution to this field.
Dr. Jerry A. Shields, a pioneering ophthalmologist, received the inaugural Brady-Shields Endowed Chair in Ocular Oncology at Wills Eye Hospital. The chair honors Dr. Luther W. Brady Jr., Dr. Carol L. Shields, and their contributions to ocular oncology research.
A group of authors from IQWiG has contradicted the American Society of Clinical Oncology's conclusion that MammaPrint can identify patients who do not require chemotherapy. The IQWiG analysis found a statistically significant disadvantage of the test for disease-free survival in certain patient groups.
The combination of chemotherapy and immunotherapy significantly improves progression-free survival in patients with advanced non-squamous NSCLC. The study showed that the addition of atezolizumab to bevacizumab and chemotherapy leads to a median PFS of 8.3 months, compared to 6.8 months with bevacizumab and chemotherapy alone.
A modified XELIRI regimen with reduced doses of irinotecan and capecitabine has been shown to be non-inferior to FOLFIRI in terms of overall survival. The treatment, combined with bevacizumab, demonstrated favourable tolerability and efficacy comparable to XELOX plus bevacizumab.
A new study estimates that there were 854,000 new cases of liver cancer and 810,000 deaths worldwide in 2015. The majority of these cases were attributed to hepatitis B virus and alcohol consumption, highlighting the need for prevention and treatment strategies.
A survey of breast cancer clinic patients found that short- and long-term side effects were often better than anticipated, with 83% and 84% of respondents reporting similar expectations. Women reported lower fears and more positive experiences after treatment, highlighting the need to address misconceptions about radiation therapy.
At ESMO 2017, researchers presented 55 late-breaking abstracts and 1,736 selected abstracts, featuring breakthrough treatments for various cancers. The Congress emphasized the importance of preventing cancer through lifestyle changes and explored sustainable treatment options.
The MONARCH 3 trial showed that adding abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone. Around one-third of women may not need a CDK 4/6 inhibitor as initial treatment.
Advance Care Planning (ACP) is a process where patients discuss their goals and preferences with relatives and health-care providers. The study recommends adapting ACP to the individual's readiness, updating conversations and documents regularly.
The ESMO-MCBS version 1.1 is the first major revision, introducing a new scale for single-arm studies in orphan diseases and for diseases with high unmet need. This updated tool will enable users to evaluate single-arm studies, previously only applicable to comparative studies.
ASTRO has recognized 43 researchers and clinical teams for their top-rated research abstracts, showcasing innovative science in radiation oncology. The Resident Clinical/Basic Science Research Abstract Award and Annual Meeting Travel Award also support early-career scientists, with a total of $45,000 in honorariums awarded.
Annals of Oncology has achieved an impressive Impact Factor score of 11.855, ranking it among the top 5% of oncology titles globally. The journal is recognized for its rapid and efficient peer-review publications on cutting-edge cancer research.
The IASLC published a comprehensive summary of the year's key developments in thoracic oncology, covering prevention, early detection, pathology, staging, surgery, adjuvant therapy, radiotherapy, and immunotherapy. The publication highlights significant progress in small cell lung cancer and malignant mesothelioma.
A phase III CONVERT trial study presented at ELCC 2017 shows that white blood cell boosting drugs are safe during concurrent chemo-radiotherapy of small cell lung cancer. The use of G-CSF had no significant negative impact on patient outcomes, supporting its use to mitigate neutropenia and increase chemotherapy delivery.
Rafal Dziadziuszko, a global leader in clinical thoracic oncology, has been awarded the Heine H. Hansen (HHH) Award by ESMO and IASLC for his lifetime contributions to lung cancer research and education globally.
A new study published in JAMA Oncology found that female adolescent and young adult cancer survivors have a higher risk of adverse birth outcomes, including preterm birth and low-birth weight. The study also suggests an increased likelihood of cesarean births among this population.
Researchers developed patient-size based diagnostic reference levels and achievable doses for 10 common CT head, neck and body examinations. The study found that using national benchmarks can reduce overall radiation dose and encourage facilities to optimize protocols.
A new study reveals that US men aged 18-59 have a high prevalence of genital HPV infection, with 45.2% of the population affected. The HPV vaccination coverage among eligible men is also low, at 10.7%, with age groups 23-27 and older showing higher rates.
Researchers found that a prostate-specific antigen (PSA) nadir greater than 0.5 ng/mL following radiation and androgen deprivation therapy identifies men prior to PSA failure who are at high risk for dying early. This marker can help identify men in need of more aggressive treatment, potentially making it curable.
A new study found a significant association between asbestos exposure and malignant mesothelioma in Eastern China. The research also highlights a notable difference in the male-to-female ratio of patients with mesothelioma, with more females affected than males.
A new analysis of 1981 patients with lower gastrointestinal symptoms found that the new criteria would miss nearly 20% of colorectal cancers. The study suggests that alarm features indicative of colorectal cancer are common among the general population, limiting their accuracy in predicting a diagnosis.
A special issue of Future Oncology examines the latest breakthroughs in prostate cancer imaging, including multiparametric MRI and PET imaging. The issue aims to provide a comprehensive overview of the field's current state and future directions.
A Phase III trial found ribociclib improved PFS of post-menopausal women with hormone receptor-positive metastatic breast cancer by 44 percent compared to hormone therapy alone. The study also showed a higher ORR in patients receiving ribociclib, with serious adverse events occurring less than five percent overall.
The phase III KEYNOTE-024 trial found pembrolizumab significantly improved progression-free survival by approximately four months compared to chemotherapy, with 80% of patients alive at six months on pembrolizumab. The treatment was also associated with a higher overall response rate and lower adverse events.
Sumitra Thongprasert has been awarded the second ESMO Women for Oncology award for her role as a role model for women in oncology. The award acknowledges her advocacy across Asia for female participation in the oncology workforce and promotion of women in leadership positions.
A new study published in JAMA Oncology found that 86% of National Comprehensive Cancer Network (NCCN) guideline authors had at least one reported financial conflict of interest. The study revealed significant payments to guideline authors, with an average of $10,011 for general payments and $236,066 for industry research payments.
Rates of early prostate cancer have continued to drop since the USPSTF recommendation, with localized/regional-stage incidence rates declining by 6-19% from 2011 to 2013. The decrease is attributed to changes in PSA testing rates and potentially unknown risk factors.
The first study assessing the clinical impact of ESMO-MCBS in a real-life context shows that the scale works reliably and reproducibly in advanced or metastatic disease. The study encourages its use in daily routine for novel treatments like immunotherapy.
The ESMO consensus guidelines reflect a personalized treatment approach to managing metastatic colorectal cancer, incorporating molecular markers and patient selection. The guidelines aim to improve outcomes by providing evidence-based recommendations for treatment options.
A large proportion of US cancer deaths might be prevented through adopting healthy lifestyles, including quitting smoking and exercising regularly. The study found that individuals who met specific criteria for a healthy lifestyle pattern had a significantly lower risk of developing cancer.
Suresh Senan, a renowned expert in radiation oncology, has been awarded the Heine H. Hansen Award for his pioneering work in lung cancer therapy and research. The award recognizes his significant contributions to the field of lung cancer on an international basis.
A multicenter study found that the HOSPITAL score accurately predicted patients at high risk of a 30-day potentially avoidable readmission. Patients identified as high risk were four times more likely to be readmitted within 30 days, and the score showed an excellent ability to identify these patients.
The Association for Molecular Pathology (AMP) has updated its pathology residency curriculum recommendations, focusing on 10 major molecular pathology topics. The new report aims to equip pathologists with the latest scientific breakthroughs and technological innovations in molecular pathology.
A study published in the American Journal of Clinical Oncology challenges the widely-held belief that low-dose radiation from medical imaging procedures can cause cancer. The authors argue that the linear no-threshold model, used to estimate cancer risks, has never been conclusively demonstrated by empirical evidence.
Dr. Norman Wolmark will present the William L. McGuire Memorial Lecture on the NSABP Clinical Trials' impact on early breast cancer management. Established in 1992, the McGuire Lectureship commemorates Dr. William McGuire's contributions to oncology.
The International Association for the Study of Lung Cancer (IASLC) has appointed Elsevier as the new publisher of its official journal, Journal of Thoracic Oncology. This partnership aims to enhance the journal's reputation and influence while expanding its global communities of contributors and readers.
The ESMO Women for Oncology Task Force aims to address inequalities among women oncologists, and the new award will be presented to Enriqueta Felip, who kick-started awareness of the lack of women oncologists in leadership roles. The award recognizes contributors who support the development of women in oncology.
BMJ has partnered with the European Society for Medical Oncology (ESMO) to publish a new open access cancer journal called ESMO Open. The journal will cover various aspects of cancer treatment and include study protocols and phase I clinical trials. It aims to provide rapid access to high-quality research on cancer care worldwide.
A large analysis suggests frequent citrus fruit and juice consumption may increase melanoma risk by 36% in people who eat them daily. The association is strongest for grapefruit, but not processed juices.
The American Society for Radiation Oncology (ASTRO) has launched a new open-access journal, Advances in Radiation Oncology, with Founding Editor Robert C. Miller, M.D. The journal will publish original research on novel retrospectives and hypothesis-generating series, with a focus on practice transformation.
The newly redesigned Oncology Central is now live, featuring a dedicated Pipelines and Trials section, webinars, and exclusive multimedia content. The platform offers easy navigation and access to peer-reviewed journal articles, regular cancer news updates, and exciting features.
Women with luminal A subtype breast cancer who are older than 60 and taking hormone therapy may not need radiation treatment, according to a new study. The research found that local breast radiation did not add benefit to their outcome, saving the healthcare system up to $3 million annually in Ontario.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline on definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer, citing 35 years of data to guide current treatment and future research. The guideline recommends RT as the ideal treatment for patients with locally advanced NSCLC.
A survey of French people aged 40-75 found that many incorrectly believed low cigarette consumption was risk-free for lung cancer. Only half of current smokers considered themselves at higher risk than the average population.
An interactive online education tool has been developed to help practicing oncologists with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) by providing feedback from an expert panel. The tool integrates clinical, histological, and molecular features into treatment plans, leading to a change in treatment cho...
The European Organisation for Research and Treatment of Cancer recently published an article discussing the management of locally advanced inoperable breast cancer. The review, led by Dr. Konstantinos Tryfonidis, examines current treatment options and future directions for improving outcomes.